PBAC Public Summary Documents – December 2024
Page last updated: 24 April 2025
Public Summary Documents relating to the December 2024 PBAC meeting.
- Aripiprazole: I.M. injection (modified release) 720 mg in 2.4 mL pre-filled syringe, I.M. injection (modified release) 960 mg in 3.2 mL pre-filled syringe; Abilify Asimtufii® – December 2024
- Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® - December 2024
The following Public Summary Documents have been updated:
March 2024 PBAC Meeting
- Adalimumab (IMID): Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen; Humira®
- Dabrafenib and Trametinib: Dabrafenib: Capsule 50 mg (as mesilate), Capsule 75 mg (as mesilate), Tablet (dispersible) 10 mg; Tafinlar®; Trametinib: Tablet 500 micrograms, Tablet 2 mg, Powder for oral solution 5 micrograms per mL (as dimethylsulfoxide), 97 mL; Mekinist®
July 2024 PBAC Meeting